Suppr
超能文献

Pomalidomide, bortezomib, and dexamethasone for newly diagnosed multiple myeloma patients with renal impairment.

作者信息

Jian Yuan, Chang Long, Shi Ming-Xia, Sun Ying, Chu Xiao-Xia, Xue Hua, Huang Wen-Rong, Shen Xu-Liang, Ma Jie, Jia Guo-Rong, Feng Ya-Qing, Xi Zhen-Fang, Zhao Yan-Hong, Ma Yan-Ping, Xiao Jing, Ma Guang-Yu, Wang Qing-Ming, Bao Li, Dong Yu-Jun, Zhou He-Bing, Sun Chun-Yan, Su Guo-Hong, Yan Yan, Qimuge Sai-Yin, Su Li-Ping, Sun Jing-Nan, Tian Wei-Wei, Sun Xiu-Li, Jing Hong-Mei, Gao Da, Chen Wen-Ming, Li Jian, Gao Wen

机构信息

Department of Hematology, Myeloma Research Center of Beijing, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.

Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

出版信息

Blood Adv. 2023 Dec 26;7(24):7581-7584. doi: 10.1182/bloodadvances.2023011428.

DOI:10.1182/bloodadvances.2023011428

PMID:37922425

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10733092/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/06d3/10733092/b4a12d391e1a/BLOODA_ADV-2023-011428-gr1.jpg

相似文献

Pomalidomide, bortezomib, and dexamethasone for newly diagnosed multiple myeloma patients with renal impairment.

Blood Adv. 2023 Dec 26;7(24):7581-7584. doi: 10.1182/bloodadvances.2023011428.

Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors.

Clin Lymphoma Myeloma. 2009 Aug;9(4):302-6. doi: 10.3816/CLM.2009.n.059.

Analysis of renal impairment in MM-003, a phase III study of pomalidomide + low - dose dexamethasone versus high - dose dexamethasone in refractory or relapsed and refractory multiple myeloma.

Haematologica. 2016 Jul;101(7):872-8. doi: 10.3324/haematol.2015.137083. Epub 2016 Apr 14.

Bortezomib and dexamethasone therapy for newly diagnosed patients with multiple myeloma complicated by renal impairment.

Clin Lymphoma Myeloma. 2009 Oct;9(5):394-8. doi: 10.3816/CLM.2009.n.077.

Subcutaneous Administration of Bortezomib in Combination with Thalidomide and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma Patients.

Biomed Res Int. 2015;2015:927105. doi: 10.1155/2015/927105. Epub 2015 Sep 6.

Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency.

Biol Blood Marrow Transplant. 2010 Aug;16(8):1115-21. doi: 10.1016/j.bbmt.2010.02.020. Epub 2010 Mar 1.

Dialysis Independence Following Combination Daratumumab, Thalidomide, Bortezomib, Cyclophosphamide, and Dexamethasone in Multiple Myeloma With Severe Renal Failure.

Clin Lymphoma Myeloma Leuk. 2020 Jul;20(7):e395-e398. doi: 10.1016/j.clml.2020.03.014. Epub 2020 Apr 7.

The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma.

Leukemia. 2013 Feb;27(2):423-9. doi: 10.1038/leu.2012.182. Epub 2012 Jul 5.

Bortezomib, Bendamustine and Dexamethasone vs Thalidomide, Bendamustine and Dexamethasone in Myeloma patients presenting with renal failure (OPTIMAL): a randomised, multi-centre phase II trial.

Blood Cancer J. 2022 Nov 29;12(11):162. doi: 10.1038/s41408-022-00758-7.

Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.

Lancet Haematol. 2016 Dec;3(12):e572-e580. doi: 10.1016/S2352-3026(16)30165-X. Epub 2016 Nov 12.

引用本文的文献

Lowering the Selinexor Dose within the Pomalidomide and Dexamethasone Combination Regimen Elicits Fewer Side Effects While Comparable Efficacy Against Relapsed/Refractory Multiple Myeloma.

Onco Targets Ther. 2025 Jun 6;18:695-703. doi: 10.2147/OTT.S516486. eCollection 2025.

Appraisal of CRISPR Technology as an Innovative Screening to Therapeutic Toolkit for Genetic Disorders.

Mol Biotechnol. 2025 Feb 2. doi: 10.1007/s12033-025-01374-z.

Pre-exposure prophylaxis with tixagevimab/cilgavimab for coronavirus disease 2019 (COVID-19) during the Omicron BA.5 wave at a single institution in Japan.

Int J Hematol. 2023 Dec;118(6):731-736. doi: 10.1007/s12185-023-03663-2. Epub 2023 Sep 25.

本文引用的文献

Multiple myeloma with acute light chain cast nephropathy.

Blood Cancer J. 2023 Mar 29;13(1):46. doi: 10.1038/s41408-023-00806-w.

Efficacy and safety of pomalidomide, bortezomib, and dexamethasone combination chemotherapy for newly diagnosed multiple myeloma: POMACE Phase II Study.

Blood Cancer J. 2023 Mar 24;13(1):45. doi: 10.1038/s41408-023-00816-8.

Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics.

Eur J Haematol. 2022 Jan;108(1):73-83. doi: 10.1111/ejh.13706. Epub 2021 Sep 22.

Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up.

Hemasphere. 2021 Feb 3;5(2):e528. doi: 10.1097/HS9.0000000000000528. eCollection 2021 Feb.

Randomized Trial Comparing Double Versus Triple Bortezomib-Based Regimen in Patients With Multiple Myeloma and Acute Kidney Injury Due to Cast Nephropathy.

J Clin Oncol. 2020 Aug 10;38(23):2647-2657. doi: 10.1200/JCO.20.00298. Epub 2020 Jun 23.

An open-label, pharmacokinetic study of lenalidomide and dexamethasone therapy in previously untreated multiple myeloma (MM) patients with various degrees of renal impairment - validation of official dosing guidelines.

Leuk Lymphoma. 2020 Aug;61(8):1860-1868. doi: 10.1080/10428194.2020.1747064. Epub 2020 May 31.

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.

Lancet Oncol. 2019 Jun;20(6):781-794. doi: 10.1016/S1470-2045(19)30152-4. Epub 2019 May 13.

Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial.

J Clin Oncol. 2018 Jul 10;36(20):2035-2043. doi: 10.1200/JCO.2017.76.1742. Epub 2018 Feb 2.

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.

Lancet Oncol. 2016 Aug;17(8):e328-e346. doi: 10.1016/S1470-2045(16)30206-6.

International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment.

J Clin Oncol. 2016 May 1;34(13):1544-57. doi: 10.1200/JCO.2015.65.0044. Epub 2016 Mar 14.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Suppr超能文献

Pomalidomide, bortezomib, and dexamethasone for newly diagnosed multiple myeloma patients with renal impairment.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译